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OBJECTIVES: Surveys based on patient registries in
headache clinics have concluded that a signiﬁcant 
proportion of headache sufferers have chronic daily
headaches (CDH). However, there is as yet no informa-
tion on the socio-economic impact of CDH in the general
population. To address this shortcoming, we have con-
ducted this study. METHODS: We have exploited the
data obtained in a recent large, nationwide study of the
clinical epidemiology of headache disorders performed 
in France (GRIM-2000). This study screened 10585 sub-
jects, representative of the total French population, and
involved face-to-face interview with 1486 subjects iden-
tiﬁed as suffering from headaches. A positive reply to
question “Do you suffer from headaches every day?” led
to a diagnosis of CDH. As well as collecting epidemio-
logical data, this study also assessed data on the clinical
presentation, quality of life, disability, and healthcare
consumption. Individuals with CDH were compared to
subjects with migraine as diagnosed according to IHS 
criteria. RESULTS: The prevalence of CDH in French
general population was 2.95%. Prevalence was signiﬁ-
cantly higher in females than in males. The CDH indi-
viduals were older than migraine sufferers. A signiﬁcant
degree of disability was conﬁrmed in CDH individuals
who scored worse than migraine sufferers. Individuals
with CDH also scored worse than individuals with
migraine for quality of life. Concerning the consumption
of healthcare resources, main results were that: (i) the
number of visits to GPs was signiﬁcantly greater in CDH
individuals than in migraine sufferers, (ii) psychiatrists
were the medical speciality most often consulted, (iii)
drug consumption was over six times higher in the CDH
group than in the migraine group. CONCLUSIONS: This
study indicates that CDH is associated with an important
burden of suffering in the general population and with
considerable expenditure in the health service.
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OBJECTIVES: Our objectives were to examine patterns
of medication switching, treatment discontinuation, and
associated costs in subjects treated with COX-2 speciﬁc
inhibitors or non-selective NSAIDs in a managed care
setting. METHODS: We conducted a retrospective claims
analysis in 19 managed care health plans in the United
States to evaluate three cohort groups treated with cele-
coxib, rofecoxib, or commonly prescribed non-selective
NSAIDs between July 1, 1999 and June 30, 2000. Medi-
cation utilization, switching, discontinuation, and costs
associated with medication switching and discontinuation
were evaluated. We used propensity score analysis to
match cohorts to reduce possible sampling selection bias.
RESULTS: 164,596 subjects were assigned to the cele-
coxib (n = 9,475), rofecoxib (n = 7,734) or non-selective
NSAID groups (n = 147,387). COX-2 speciﬁc inhibitor
users were signiﬁcantly less likely to switch therapy (23%
less likely by odds ratio test [p < 0.001]) and had a lower
rate of discontinuation compared to NSAID users (7.2 
vs. 18.7 discontinuations per 1000). Cox proportional
hazards analysis demonstrated that persistency on
therapy is higher for COX-2 users (57% less likely to dis-
continue) versus NSAID users. Patients remained longer
on celecoxib before discontinuation compared to subjects
in any other cohort (celecoxib 63.7 days, rofecoxib 
58.9 days, ibuprofen 21.1 days, naproxen 27.8 days, 
and diclofenac 34.4 days). Age was also associated with
longer time on therapy, with older age decreasing the like-
lihood of discontinuation by 2%. Switching therapy
increased total costs by 21.9% (p < 0.01). Outpatient,
inpatient, and emergency room costs increased in subjects
who switched therapy compared to those who remained
on therapy, when COX-2 speciﬁc inhibitor and NSAID
matched cohorts were compared. CONCLUSIONS: Less
medication switching and longer persistency were seen in
patients treated with COX-2 speciﬁc inhibitors. Medica-
tion switching was associated with increased treatment
costs. The increased resource use may be ascribed to
adverse events, which may be higher in the non-selective
NSAID cohorts.
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OBJECTIVES: Prior studies of direct costs of back pain
have primarily used Workman’s Compensation claims,
resulting in varying cost estimates and limiting generali-
zibility of ﬁndings to speciﬁc employee groups. The objec-
tives of this study were to determine the direct costs of
back pain among the general population and to stratify
those costs by type of medical care. METHODS: Retro-
spective analysis was conducted of the 1996 Medical
Expenditure Panel Survey. The survey ﬁles included 
data collected from a nationally representative sample of
22,601 respondents and from respondents’ medical care
and health insurance providers. Data included medical
conditions, use and payments for medical care, and 
health insurance and employment information. Back pain
patients were identiﬁed using ICD-9-CM codes deter-
mined by an expert panel of physicians and coders as
indicative of back pain. Direct costs were calculated using
patient and third-party payments for back pain related
medical events by category of back pain and type of
medical care. Sample estimates were projected to the pop-
ulation and 95 percent conﬁdence limits were calculated
using the Taylor expansion method. RESULTS: The direct
